Selective D2 antagonist market - Global Industry Analysis 2014 - 2018 and Forecast 2019 - 2029


Selective D2- Antagonist  Market
  • To Be Published : Nov-2020 |
  • Status : Work in progress |
  • Format : Selective D2- Antagonist  Market Selective D2- Antagonist  Market Selective D2- Antagonist  Market Selective D2- Antagonist  Market

Selective D2 antagonist is a class of dopamine antagonist drug type which blocks the dopamine receptor by a process called receptor antagonism. Most of the D2 antagonist are antipsychotics drugs which are helpful in treating mental disorders like schizophrenia, bipolar disorders, etc. These D2 receptors are found in several part of the body such as substantia nigra, hypothalamus, striatum, cortex, etc. There is high demand of selective D2 antagonist drugs due to increasing cases of mental disorders and depression. Market players are trying to expand the therapeutic application of selective D2 antagonist drugs thus creating more opportunity and scope for the growth of the selective D2 antagonist market in the future.

Rising prevalence rate of mental disorders like schizophrenia and bipolar disorders are major factors driving growth of the selective D2 antagonist market.  Expanding therapeutic use of these drugs by key market players are further expected to aid in the growth of the selective D2 antagonist market. The increasing awareness of people towards mental health is further anticipated to boost in growth of the selective D2 antagonist market. High investment in research and development of these selective D2 antagonist drugs are further expected to fuel the growth of the selective D2 antagonist market. Increasing cases of depression and other mental illness may surge in the growth of the selective D2 antagonist market. However, there are several side effects associated with the use of selective D2 antagonist drugs which in turn hamper the growth of the selective D2 antagonist market.

The selective D2 antagonist market is segmented on the basis of application, route of administration and distribution channel.

Based on drug class, the selective D2 antagonist market is segmented into

  • Droperidol
  • Metoclopramide
  • Paliperidone palmitate
  • Lurasidone hydrochloride
  • Tiapride
  • Haloperidol
  • Asenapine
  • Chlorpromazine
  • Aripiprazole
  • Risperidone
  • Others

Based on application, the selective D2 antagonist market is segmented into

  • Schizophrenia
  • Bipolar disorder
  • Dementia
  • Unipolar depression
  • Others

Based on route of administration, the selective D2 antagonist market is segmented into

  • Oral route administration
  • Intravenous
  • intramuscular

Based on distribution channel, the selective D2 antagonist market is segmented into

  • Hospital pharmacies
  • Retail pharmacy
  • Drug stores
  • online

Selective D2 antagonist drug market is expected to have robust growth over the forecast period. Among the application segment, schizophrenia segment is expected to dominate the selective D2 antagonist market. This is attributed to the increasing cases of schizophrenia globally. By route of administration the selective D2 antagonist market is classified into oral, intravenous, and intramuscular. The intravenous segment is expected to dominate the selective D2 antagonist market. By distribution channel type, retail pharmacy is expected to dominate the market owing to higher patient footfall.

The North America is accounted for significant market share in terms of revenue and is expected to dominate the selective D2 antagonist market over the forecast period. This is attributed to the rising mental patients and presence of market players in the region. Also, intensive research and development activities is further aiding in the growth of the selective D2 antagonist market. Europe is accounted for second most lucrative region due to higher adoption of selective D2 antagonist drugs. Also improved healthcare facilities and FDA approval of several selective D2 antagonist drugs in the region is further expected to drive the growth of the Selective D2 antagonist market in the region. The Asia Pacific is expected to register prominent growth in the near future, owing to the increasing cases of depression and rising awareness of people towards mental healthcare in the region. The higher disposable income of the people and increasing healthcare per capita is also contributing to the selective D2 antagonist market growth.

The major key players operating in the selective D2 antagonist market are Novartis pharmaceutical corp, Alaven pharmaceuticals LLC., Pfizer,Inc., Janssen Pharmaceuticals, Inc., Sunovion Pharmaceuticals Inc., Intas pharmaceuticals Ltd., Allergan,inc., Sanofi- Aventis, Otsuka Pharmaceutical Co., Ltd., Endo Pharmaceuticals, Inc., GlaxoSmithKline, and APP Pharmaceuticals, LLC.

The report covers exhaustive analysis on:

  • Selective D2 Antagonist Market Segments
  • Selective D2 Antagonist Market Dynamics
  • Historical Actual Market Size, 2013 - 2017
  • Selective D2 Antagonist Market Size & Forecast 2018 to 2024
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Market Drivers and Restraints 

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Selective D2- Antagonist Market

Back To Top